Navigation Links
Sanofi-aventis Announces Second Quarter 2009 Results
Date:7/29/2009

Research and development expenses rose by 1.6% to euro 1,108 million. At constant exchange rates, they were down by 2.5%, reflecting selectivity in R&D projects and cost savings.

Selling and general expenses increased by 5.9%, or 1.5% at constant exchange rates, to euro 1,895 million. The ratio of selling and general expenses to net sales fell by 1.2 points to 25.5%, reflecting the ongoing program of adaptation to market conditions.

Other current operating income, net of expenses totaled euro 132 million, compared with euro 74 million for the second quarter of 2008. The year-on-year change in this line reflects gains on currency hedging and an increase in the royalty collected by sanofi-aventis on sales of Copaxone((R)) in North America.

Operating income - current was up 26.8% at euro 3,046 million. At constant exchange rates, growth was 16.0%. The ratio of operating income - current to net sales improved by 5.1 points to 41.0%.

Net financial expenses were virtually unchanged at euro 70 million. Financial expenses rose slightly, reflecting the change in net debt arising from payment of the Zentiva purchase consideration at the end of the first quarter and from the dividend payout.

The effective tax rate was 0.6 of a point lower at 29%, in line with the 2008 full-year rate.

The share of profits from associates was up 22.6% at euro 266 million, with the share of after-tax profits from territories managed by BMS under the Plavix((R)) and Avapro((R)) alliance 42.7% higher at euro 207 million due to a good performance by Plavix((R)) in the United States and a favorable dollar effect. The contribution from Merial rose by 21.6%, and the contribution from Sanofi Pasteur MSD also grew.

Minority interests were 5.7% higher at euro 111 million. The share of pre-tax profits paid to BM
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
5. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
6. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
8. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
9. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... LC Sciences LLC, a leading developer ... it is seeking beta testers for the VariantPro™ ... targeted sequencing technology. The system offers cost-effective, minimal ... detection of rare variants. It utilizes novel and ... will collaborate with beta testers to generate test ...
(Date:4/16/2015)... Francisco, CA (PRWEB) April 16, 2015 ... scheduled to report first quarter results on Thursday, April ... announcement, Cytokinetics’ senior management will host a conference call ... financial results and the company’s outlook for the future. ... can be accessed from the homepage and in the ...
(Date:4/16/2015)... April 16, 2015 According to ... involving an outside source was ranked first among ... injuries related to lifting, pushing, pulling, holding, carrying, ... direct costs. The David Round Company takes statistics ... to working hard to develop and design equipment ...
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
Breaking Biology Technology:LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
... 23 BioDuro and AstraZeneca announced today that ... discovery research for Respiratory and Inflammation indications. BioDuro ... of discovery chemistry, discovery biology, ADMET*, and DMPK** ... discovery and shorten development timelines. "After a successful ...
... Food Industry Professional Lends Experience To Antimicrobial Leader.SHREVEPORT, ... the country,s foremost authorities in the poultry industry, ... years of poultry expertise to SteriFx, a leader ... processing, food safety, healthcare, defense and other industries. ...
... ("BVF") today announced that PROXY Governance, widely recognized as a ... for all BVF Proposals on the GOLD proxy card for ... ) to be held on March 27, 2009.In its report ... (BVF) must clear a high bar to justify a change ...
Cached Biology Technology:BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications 2Dan Blackshear Joins SteriFx Inc. 2Leading Advisory Firm, PROXY Governance, Recommends Avigen Shareholders Vote on GOLD Card to Remove Incumbent Directors and Elect BVF's Stockholder-Oriented Nominees 2
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
(Date:3/26/2015)... -- The Granite Club, Canada,s ... today announced it has implemented a state-of-the-art access and ... members and staff, while restricting access to authorized users ... FST,s IMID Access system because it has the perfect ... staff, in addition to unparalleled security," said James ...
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ... Biometrics - Global Strategic Business Report" report to their offering. ... Voice Biometrics in US$ Thousands by the following Segments: Face Biometrics, ... US, Canada , Japan , ... Middle East & Africa , ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... changes to a gene that do not alter ... bipolar disorder. This is the first epigenome-wide investigation ... be a significant step on the journey to ... senior scientist in the Krembil Family Epigenetic Laboratory ...
... WALL, N.J., March 10 BIO-key International,Inc. (OTC Bulletin Board: ... 2007 financial results on Monday, March 17, 2008,after the market ... call, which will be broadcast live over the Internet,on Tuesday, ... What: BIO-key International, Inc. Fourth Quarter and Full ...
... Bethesda, MD A new and notable article ... Narrow Pore appears in Volume 94, Issue 5, of ... Passage Times for Polymer Translocation Pulled through ... through a nanometer-sized pore in membranes, in a process ...
Cached Biology News:Epigenetic changes discovered in major psychosis 2BIO-key(R) Announces Fourth Quarter and Full Year 2007 Earnings Release and Conference Call Schedule 2Media highlights for February in Biophysical Journal 2
Special grade: for electrophoresis...
... DAPI (4,6-diamidine-2-phenylindole, dihydrochloride) is ... the nucleus blue in color. ... excellent contrast to red fluorochromes ... Red, or R-Phycoerythrin. DAPI can ...
Contact us for more information...
... sensitive silver stain. Reproducible ... baths or reversers needed. ... polysaccharides. Linear protein-to-stain color ... multiple gels per tray. ...
Biology Products: